CD274 and neoplasm: Predictive biomarkers refer to biological characteristics that can predict a patient’s response to immune checkpoint inhibitor treatment, including PD-L1 expression, immune cell infiltration, tumor mutation burden (TMB), circulating markers, and microbiome composition.